At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA + V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML)
In Brief
A Phase 3 clinical trial evaluating Allogeneic Hematopoietic Stem Cell Transplantation, Cytarabine, and 4 other interventions for Acute Myeloid Leukemia and Untreated Adult Acute Myeloid Leukemia. Completed, enrolled 754 participants across 447 sites in 2 countries.
Detailed Summary
This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without vorinostat to see how well they work in treating younger patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine, daunorubicin hydrochloride, idarubicin, and vorinostat, work in different ways to stop the growth of cancer cells, either by killing the cells, stopping them from dividing, or by stopping from spreading. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells. It is not yet known which combination chemotherapy is more effective in treating acute myeloid leukemia.
Study Details
Timeline
Interventions
Undergo allogeneic transplant
Given IV
Given IV
Given IV
Correlative studies
Given PO